Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
Thirty-nine patients with psoriasis undergoing PUVA participated in a prospective double-blind study of acute non-phototoxic adverse effects comparing the liquid formulations of 8-methoxypsoralen (0.6 mg/kg) and 5-methoxypsoralen (1.2 mg/kg). A much higher number of patients experienced nausea (8-MOP = 51.3%, 5-MOP = 7.7%) and pruritus (8-MOP = 71.8%, 5-MOP = 43.6%) than has been reported for crystalline tablets. No attempt was made to compare therapeutic efficacy between liquid and crystalline tablet formulations or between 8-MOP and 5-MOP, which both appeared to be effective. The high incidence of adverse effects suggests that current dosage recommendations be reviewed.
George
S A
SA
Department of Dermatology, Ninewells Hospital and Medical School, Dundee, United Kingdom, Scotland.
Ferguson
J
J
D000078223:5-Methoxypsoralen; D000328:Adult; D000368:Aged; D004304:Dosage Forms; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D008875:Middle Aged; D011701:PUVA Therapy; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy
D004304:Dosage Forms; D000078223:5-Methoxypsoralen; D008730:Methoxsalen